Trial *
Publication Hannawi S, J Infect, 2022
Primary outcome on the report: 1) incidence and severity of adverse reactions (ARs) within 7 days after vaccination, adverse events (AEs) within 7 days, unsolicited AEs within 28 days, laboratory abnormalities related AEs within 14 days, serious adverse events (SAEs), AEs of special interest (AESIs) and medically attended AEs (MAAEs) within 365 days, after vaccination. 2) geometric mean concentration (GMC) of the specific spike binding IgG antibodies against spike protein of wild-type SARS-COV-2 strain on day 28 after vaccination (D28) and GMTs of neutralizing antibodies (live virus neutralization assay) to Delta (B.1.617.2) and Omicron (B.1.1.529) variants on D28, and the fold increase of these GMC and GMT from baseline (before vaccination).

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.